Aging CellNeurosciencePeer-reviewed journal article
The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons
Taylor RussoiD, Benjamin KolisnykiD, B.S. AswathyiD, Tae Wan KimiD, Jacqueline MartiniD, Jonathan Plessis‐BelairiD, Jason Ni, Jordan A. PearsoniD, Emily J. ParkiD, Roger B. SheriD, Lorenz StuderiD, Markus RießlandiD
Abstract
Idiopathic Parkinsons Disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, which is associated with neuroinflammation and reactive gliosis. The underlying cause of PD and the concurrent neuroinflammation are not well understood. In this study, we utilized human and murine neuronal lines, stem cell-derived dopaminergic neurons, and mice to demonstrate that three previously identified genetic risk factors for PD, namely SATB1, MIR22HG, and GBA, are components of a single gene regulatory pathway. Our findings indicate that dysregulation of this pathway leads to the upregulation of glucocerebrosides (GluCer), which triggers a cellular senescence-like phenotype in dopaminergic neurons. Specifically, we discovered that downregulation of the transcriptional repressor SATB1 results in the derepression of the microRNA miR-22-3p, leading to decreased GBA expression and subsequent accumulation of GluCer. Furthermore, our results demonstrate that an increase in GluCer alone is sufficient to impair lysosomal and mitochondrial function, thereby inducing cellular senescence dependent on S100A9 and stress factors. Dysregulation of the SATB1-MIR22-GBA pathway, observed in both PD patients and normal aging, leads to lysosomal and mitochondrial dysfunction due to the GluCer accumulation, ultimately resulting in a cellular senescence-like phenotype in dopaminergic neurons. Therefore, our study highlights a novel pathway involving three genetic risk factors for PD and provides a potential mechanism for the senescence-induced neuroinflammation and reactive gliosis observed in both PD and normal aging.
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- research focus: gene regulatory network inference
- research focus: differential expression
- research focus: cell type annotation
- approach: statistical model
- approach: experimental assay
- Citations
- 31
- FWCI
- 8.29
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of SATB1 Induces a p21 Dependent CellularSenescence Phenotype in Dopaminergic Neurons
Markus Rießland, Benjamin Kolisnyk, … Paul Greengard·Cell stem cellPeer-reviewed·Sep 19, 2019
- Diverging Parkinson's Disease Pathology between GBAN370S ,LRRK2G2019S and engineered SNCAA53T iPSC-derived Dopaminergic Neurons
Ali Fathi, Kiranmayee Bakshy, … Jing Liu·bioRxiv·Jan 6, 2023
- Extracellular S100B alters spontaneous Ca2+ fluxes in dopaminergic neurons via L-type voltage gated calcium channels: Implications for Parkinson's disease
Eric A. Bancroft, Gauri Pandey, … Rahul Srinivasan·bioRxiv·Feb 24, 2021
- GBA1 mutations alter neuronal firing and structure, regulating VGLUT2 and CRYAB in dopamine neurons
Eva Rodríguez‐Traver, Luz M. Suárez, … Carlos Vicario‐Abejón·bioRxiv·Aug 5, 2024
- Synaptic dysfunction and dysregulation of extracellular matrix-related genes in dopaminergic neurons derived from Parkinson's disease sporadic patients and with GBA1 mutations
Idan Rosh, Utkarsh Tripathi, … Shani Stern·bioRxiv·Apr 10, 2023
- Microglial low-affinity FcγR mediates the phagocytic elimination of dopaminergic neurons in Parkinsons disease degeneration
Paola V. Casanova, Irina Freitag-Berenguel, … Carlos Barcia·npj Parkinson s DiseasePeer-reviewed·Jan 16, 2026